4D Molecular Therapeutics FDMT

$ 7.65 -4.26%

Quarterly report 2024-Q3
added 11-13-2024

4D Molecular Therapeutics Balance Sheet 2011-2024 | FDMT

Annual Balance Sheet 4D Molecular Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-234 M	-36.2 M	-137 M	-277 M	-49.7 M	-91.8 M	-23.8 M	-	-	-	-	-	-
Long Term Debt	11.5 M	13.5 M	15.2 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	3.15 M	2.66 M	1.23 M	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	15.2 M	118 M	117 M	41 M	-	-	-	-	-	-
Total Current Liabilities	19 M	15.7 M	16.3 M	16.7 M	-	-	-	-	-	-	-	-	-
Total Liabilities	32.1 M	30.5 M	34.4 M	31.9 M	131 M	125 M	46.9 M	-	-	-	-	-	-
Deferred Revenue	273 K	884 K	2.6 M	6.59 M	5.86 M	4.91 M	4.38 M	-	-	-	-	-	-
Retained Earnings	-415 M	-314 M	-207 M	-136 M	-79 M	-30 M	-20.5 M	-	-	-	-	-	-
Total Assets	340 M	262 M	353 M	288 M	58.2 M	97 M	27.3 M	-	-	-	-	-	-
Cash and Cash Equivalents	249 M	52.4 M	153 M	277 M	-	-	-	-	-	-	-	-	-
Book Value	308 M	231 M	319 M	256 M	-73 M	-27.6 M	-19.6 M	-	-	-	-	-	-
Total Shareholders Equity	308 M	231 M	319 M	256 M	-73 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet 4D Molecular Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	19.7 M	10.5 M	11 M	11.5 M	12 M	12.5 M	-	13.5 M	13.9 M	14.4 M	14.8 M	15.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	51.1 M	31.8 M	29.3 M	32.1 M	31.7 M	27.4 M	-	30.5 M	28.7 M	30.4 M	28.9 M	34.4 M	16.5 M	14.3 M	27.7 M	31.9 M	31.9 M	31.9 M	31.9 M	28.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	35 K	-	-	273 K	130 K	576 K	-	884 K	2.21 M	2.26 M	2.11 M	2.6 M	1.73 M	3.02 M	7.09 M	6.59 M	6.59 M	6.59 M	6.59 M	5.86 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-527 M	-483 M	-448 M	-415 M	-383 M	-373 M	-	-314 M	-287 M	-261 M	-233 M	-207 M	-182 M	-160 M	-152 M	-136 M	-136 M	-136 M	-136 M	-79 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	604 M	620 M	630 M	340 M	362 M	353 M	-	262 M	280 M	303 M	325 M	353 M	241 M	255 M	270 M	288 M	288 M	288 M	288 M	58.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	188 M	189 M	276 M	249 M	276 M	236 M	-	52.4 M	108 M	113 M	76 M	153 M	91 M	244 M	260 M	277 M	277 M	277 M	277 M	49.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	553 M	588 M	601 M	308 M	330 M	325 M	-	231 M	251 M	273 M	296 M	319 M	224 M	241 M	242 M	256 M	256 M	256 M	256 M	30 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	553 M	588 M	601 M	308 M	330 M	325 M	219 M	231 M	251 M	273 M	296 M	319 M	224 M	241 M	242 M	256 M	256 M	256 M	256 M	-73 M	-	-	-	-27.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency